Spago Nanomedical AB - Asset Resilience Ratio

Latest as of December 2016: 54.03%

Spago Nanomedical AB (SPAGO) has an Asset Resilience Ratio of 54.03% as of December 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Skr43.26 Million
≈ $4.66 Million USD Cash + Short-term Investments

Total Assets

Skr80.06 Million
≈ $8.62 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Spago Nanomedical AB's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Spago Nanomedical AB to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Spago Nanomedical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SPAGO stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr0.00 0%
Short-term Investments Skr43.26 Million 54.03%
Total Liquid Assets Skr43.26 Million 54.03%

Asset Resilience Insights

  • Very High Liquidity: Spago Nanomedical AB maintains exceptional liquid asset reserves at 54.03% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Spago Nanomedical AB Industry Peers by Asset Resilience Ratio

Compare Spago Nanomedical AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Biotechnology 46.79%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 63.47%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for Spago Nanomedical AB (None–None)

The table below shows the annual Asset Resilience Ratio data for Spago Nanomedical AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points

About Spago Nanomedical AB

ST:SPAGO Sweden Biotechnology
Market Cap
$8.33 Million
Skr77.40 Million SEK
Market Cap Rank
#27505 Global
#600 in Sweden
Share Price
Skr0.12
Change (1 day)
+0.43%
52-Week Range
Skr0.09 - Skr0.33
All Time High
Skr19.04
About

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well… Read more